- Home
- ARMN vs STOK Comparison
ARMN vs STOK Comparison
Compare ARMN & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMN
- STOK
- Stock Information
- Founded
- ARMN 1992
- STOK 2014
- Country
- ARMN Canada
- STOK United States
- Employees
- ARMN N/A
- STOK N/A
- Industry
- ARMN
- STOK Biotechnology: Pharmaceutical Preparations
- Sector
- ARMN
- STOK Health Care
- Exchange
- ARMN Nasdaq
- STOK Nasdaq
- Market Cap
- ARMN 2.0B
- STOK 1.7B
- IPO Year
- ARMN N/A
- STOK 2019
- Fundamental
- Price
- ARMN $13.99
- STOK $31.21
- Analyst Decision
- ARMN Strong Buy
- STOK Strong Buy
- Analyst Count
- ARMN 1
- STOK 9
- Target Price
- ARMN $17.00
- STOK $31.00
- AVG Volume (30 Days)
- ARMN 1.4M
- STOK 1.2M
- Earning Date
- ARMN 10-29-2025
- STOK 11-04-2025
- Dividend Yield
- ARMN N/A
- STOK N/A
- EPS Growth
- ARMN N/A
- STOK N/A
- EPS
- ARMN 0.26
- STOK 0.68
- Revenue
- ARMN $770,175,000.00
- STOK $205,632,000.00
- Revenue This Year
- ARMN $82.77
- STOK $416.54
- Revenue Next Year
- ARMN $73.80
- STOK N/A
- P/E Ratio
- ARMN $57.70
- STOK $45.58
- Revenue Growth
- ARMN 58.96
- STOK 1128.17
- 52 Week Low
- ARMN $3.29
- STOK $5.35
- 52 Week High
- ARMN $14.03
- STOK $38.69
- Technical
- Relative Strength Index (RSI)
- ARMN 77.77
- STOK 61.85
- Support Level
- ARMN $11.25
- STOK $28.51
- Resistance Level
- ARMN $12.17
- STOK $29.38
- Average True Range (ATR)
- ARMN 0.60
- STOK 2.02
- MACD
- ARMN 0.28
- STOK 0.55
- Stochastic Oscillator
- ARMN 99.66
- STOK 100.00
About ARMN Aris Mining Corporation
Aris Mining Corp is engaged in the acquisition, exploration, development, and operation of gold properties in Colombia, Guyana, and Canada. It owns and operates its Segovia Operations, Soto Norte Project and Marmato Mine in Colombia, the Toroparu Project in Guyana, and the Juby Project in Ontario, Canada. The company generates revenue from the sale of gold and silver.
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.